Table 4.
Duration of hypoglycemia according to concomitant antidiabetic medications
| Duration (min/h) | Duration (min/h) | P | |
|---|---|---|---|
| (+) | (−) | ||
| Hypoglycemia of <54 mg/dL | |||
| Incretin‐related agents (DPP‐4 inhibitors or GLP‐1 receptor agonists)† | 0.54 (n = 241) | 0.82 (n = 28) | 0.42 |
| DPP‐4 inhibitors | 0.55 (n = 224) | 0.67 (n = 45) | 0.67 |
| GLP‐1 receptor agonists | 0.40 (n = 18) | 0.58 (n = 251) | 0.66 |
| Biguanides | 0.63 (n = 183) | 0.43 (n = 86) | 0.38 |
| Thiazolidinediones | 0.44 (n = 40) | 0.59 (n = 229) | 0.60 |
| SGLT‐2 inhibitors | 0.37 (n = 36) | 0.6 (n = 233) | 0.47 |
| Alpha‐glucosidase inhibitors | 0.41 (n = 78) | 0.63 (n = 191) | 0.33 |
| Hypoglycemia of <70 mg/dL | |||
| Incretin‐related agents (DPP‐4 inhibitors or GLP‐1 receptor agonists)† | 2.3 (n = 241) | 3.8 (n = 28) | <0.05 |
| DPP‐4 inhibitors | 2.3 (n = 224) | 3.2 (n = 45) | 0.15 |
| GLP‐1 receptor agonists | 2.1 (n = 18) | 2.5 (n = 251) | 0.69 |
| Biguanides | 2.7 (n = 183) | 1.9 (n = 86) | 0.13 |
| Thiazolidinediones | 2.6 (n = 40) | 2.4 (n = 229) | 0.85 |
| SGLT‐2 inhibitors | 2.3 (n = 36) | 2.5 (n = 233) | 0.77 |
| Alpha‐glucosidase inhibitors | 1.8 (n = 78) | 2.7 (n = 191) | 0.07 |
Data are adjusted by glycated hemoglobin level. †One participant administered both a dipeptidyl peptidase‐4 (DPP‐4) inhibitor and a glucagon‐like peptide‐1 (GLP‐1) receptor agonist. SGLT‐2, sodium–glucose cotransporter 2